Mepolizumab, a fully humanized anti-IL-5 mAb, showed improvement in symptoms, endoscopic features, and esophageal eosinophil counts but no histologic remission in several studies examining its efficacy in EoE [157,158]. The gene discussed is IL5; the disease is eosinophilic esophagitis.